Although the most common primary treatment for HR+ breast cancers have come from targeting ESR signaling, there has recently been renewed interest in utilizing the new synthetic PGR-specific ligands, such as mifepristone (commonly known as RU486), norethindrone, and mometasone furoate, for breast cancer management 6,7. This evidence concerns the gene ESR1 and breast cancer.